Hsa-miR-106a在胃癌组织中的表达及其临床意义  

Expression of hsa-miR-106a in gastric carcinoma and its clinical significance

作　　者：郭波[1] 王文静[2] 赵凌宇[1] 常素娥 童东东 杨阳[1] 宋土生[1] 黄辰[1,3] 

机构地区：[1]西安交通大学医学院遗传学与分子生物学系,西安710061 [2]西安交通大学医学院第一附属医院肝胆外科 [3]西安交通大学医学院心血管研究中心

出　　处：《山西医科大学学报》2014年第1期12-15,共4页Journal of Shanxi Medical University

基　　金：陕西省科技攻关项目重大科技专项基金资助项目(2010ZDKG-50)

摘　　要：目的分析hsa-miR-106a在胃癌组织中相对于正常组织的表达及其与病理分级及临床分期的关系。方法从石蜡组织包埋的19例胃癌及19例正常组织中提取总RNA,应用Real-time PCR方法检测miR-106a的表达情况,并分析其与胃癌病理分级及临床分期的关系。结果 miR-106a在胃癌组织中有14例高表达,5例低表达,在胃癌组织中的表达明显高于正常组织(P<0.01),其表达与胃癌的病理分级、临床分期密切相关。结论 miR-106a可能参与了胃癌的发生、发展过程。Objective To investigate the expression of hsa-miR-106a in gastric cancer and explore its clinical significance. Methods Total RNA was extracted from 19 pairs of gastric cancer tissues and normal tissues. The expression levels of miR-106a were detected by quantitative reverse transcriptase polymerase chain reaction. The association between miRNA expression and clinicopathological fea- tures was investigated. Results The miR-106a was highly expressed in 14 cases of gastric cancer, and the level was significantly higher in gastric cancer tissues than that in normal tissues（ P 〈 0.01 ）. The miR-106a expression in gastric tumor was associated with the pathological grading and clinical stage（P 〈 0. 05） Conclusion These results suggest that hsa-miR-106a might be involved in the progression and development of gastric cancer.

关 键 词：hsa-miR-106a 微小RNA 胃癌 病理分级 

分 类 号：R735.2[医药卫生—肿瘤]